Wavefront: many measurements, deep analysis, one cut

Article

The carpenter's rule is measure twice, cut once. The wavefront aberrometry rule should be measure hundreds of times, then analysed, and then cut once, Dr Robert Iskander said.

The carpenter's rule is measure twice, cut once. The wavefront aberrometry rule should be measure hundreds of times, then analysed, and then cut once, Dr Robert Iskander said.

He remarked that the eye is not a piece of plastic but is part of a complex dynamic system and refractive results vary over time. "In the human eye we observe temporal changes in accommodation and wavefront aberrations, eye movements, like microsaccades, drift and tremor. And we observe temporal changes in surface characteristics, like the dynamics of tear film or corneal deformation."

Focusing on issues in wavefront aberrometry, he said it is better to use open view wavefront sensing. "Defogging may lead to inconsistent results and instrument myopia," he added. It is also important to use pupil rescaling, especially when the pupil is small.

"Do not extrapolate the pupil size, in other words do not rescale from a smaller to a larger size, and use a number of acquisitions. For example, for COAS wavefront sensor we use four measurements of 30 samples at approximately 10Hz," he affirmed.

The measurements of the dynamic wavefront aberration are estimates of the true refractive state of the eye. "For example, if a patients spends half an hour reading in your waiting room before the measurements are taken, that's going to have an effect on the result," he said.

But measurements taken at another time could give a different result. That's why multiple measurements, and serious analysis of what those measurements represent, are essential before deciding on a surgical strategy.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.